KRAS mutation could upregulate the expression of PD-L1 in tumor cells by different mechanisms including improving the stability of PD-L1 mRNA, promoting ROS production and inducing FGFR1 expression in lung cancer56,57. This evidence concerns the gene CD274 and neoplasm.